These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35881220)

  • 1. The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy.
    Yao H; Xu W; Liu Y; Cao Z; Wen J; Zhang M; Wu Z; Yan X; Jiao Z; Zhang Z; Chen J; Zhang M; Zhu WG; Wang D
    Sci China Life Sci; 2023 Jan; 66(1):81-93. PubMed ID: 35881220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B56γ tumor-associated mutations provide new mechanisms for B56γ-PP2A tumor suppressor activity.
    Nobumori Y; Shouse GP; Wu Y; Lee KJ; Shen B; Liu X
    Mol Cancer Res; 2013 Sep; 11(9):995-1003. PubMed ID: 23723076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.
    Shouse GP; Cai X; Liu X
    Mol Cell Biol; 2008 Jan; 28(1):448-56. PubMed ID: 17967874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.
    Shouse GP; Nobumori Y; Liu X
    Oncogene; 2010 Jul; 29(27):3933-41. PubMed ID: 20473327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.
    Li HH; Cai X; Shouse GP; Piluso LG; Liu X
    EMBO J; 2007 Jan; 26(2):402-11. PubMed ID: 17245430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development.
    Jin Z; Wallace L; Harper SQ; Yang J
    J Biol Chem; 2010 Nov; 285(45):34493-502. PubMed ID: 20807766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HEAT repeat 1 motif is required for B56γ-containing protein phosphatase 2A (B56γ-PP2A) holoenzyme assembly and tumor-suppressive function.
    Nobumori Y; Shouse GP; Fan L; Liu X
    J Biol Chem; 2012 Mar; 287(14):11030-6. PubMed ID: 22315229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
    Kauko O; Westermarck J
    Int J Biochem Cell Biol; 2018 Mar; 96():157-164. PubMed ID: 29355757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
    Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
    Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The B55α subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation.
    Reid MA; Wang WI; Rosales KR; Welliver MX; Pan M; Kong M
    Mol Cell; 2013 Apr; 50(2):200-11. PubMed ID: 23499005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
    Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
    J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.